Vertex Pharmaceuticals Inc/ US92532F1003 /
8/26/2024 4:10:59 PM | Chg. - | Volume | Bid2:53:01 PM | Ask2:58:58 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
434.05EUR | - | 2 Turnover: 868.10 |
425.75Bid Size: 14 | 430.20Ask Size: 100 | 110.18 bill.EUR | - | - |
Assets
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 715.8120 | 697.7150 | 698.3620 | 789.4370 | 812.0050 | ||||||
Intangible Assets | 29 | 284.3400 | 284.3400 | 29 | - | ||||||
Long-Term Investments | - | - | 20.2760 | 20.4470 | - | ||||||
Fixed Assets | 788.1680 | 1,091.7220 | - | 897.0510 | 2,402.7890 | ||||||
Inventories | 30.8480 | 57.2070 | 77.6040 | 111.8300 | 124.3600 | ||||||
Accounts Receivable | 75.9640 | 177.6390 | 201.0830 | 281.3430 | 409.6880 | ||||||
Cash and Cash Equivalents | 625.2590 | 714.7680 | 1,183.9450 | 1,665.4120 | 2,650.1340 | ||||||
Current Assets | 1,546.5110 | 1,407.1530 | 1,831.5400 | 2,648.9630 | 3,843.1090 | ||||||
Total Assets | 2,334.6790 | 2,498.8750 | 2,896.7870 | 3,546.0140 | 6,245.8980 |
Liabilities
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 71.1940 | 74.9420 | 61.4510 | 73.9940 | 110.9870 | ||||||
Long-term debt | 792.9350 | 739.3970 | 521.3350 | 583.9020 | 581.5500 | ||||||
Liabilities to Banks | 280.6000 | 224 | 0.0000 | 0.0000 | 0.0000 | ||||||
Provisions | - | 110.4000 | 134.1000 | 6.3000 | - | ||||||
Liabilities | 1,238.4960 | 1,405.2470 | 1,558.5960 | 1,503.7080 | 1,810.6950 | ||||||
Share Capital | 2.3850 | 2.4270 | 2.4500 | 2.5120 | 2.5460 | ||||||
Total Equity | 1,096.1830 | 1,093.6280 | 1,338.1910 | 2,042.3060 | 4,435.2030 | ||||||
Minority Interests | 21.1770 | 153.6610 | 181.6090 | 13.7270 | 0.0000 | ||||||
Total liabilities equity | 2,334.6790 | 2,498.8750 | 2,896.7870 | 3,546.0140 | 6,245.8980 |
Income Statement
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 580.4150 | 1,032.3360 | 1,702.1770 | 2,488.6520 | 3,047.5970 | ||||||
Depreciation (total) | 63.2570 | 62.3430 | 61.3980 | 61.3970 | 72.4200 | ||||||
Operating Result | -692.4120 | -466.8790 | 9.9360 | 123.2430 | 635.1500 | ||||||
Interest Income | 72.8630 | 84.2060 | 81.4320 | 57.5500 | 34.1190 | ||||||
Income Before Taxes | -734.8750 | -557.8000 | -67.3660 | -15.6890 | 600.2410 | ||||||
Income Taxes | 6.9580 | 30.3810 | 16.6650 | -107.3240 | -1,486.8620 | ||||||
Minority Interests Profit | 4.1900 | 31.8470 | -28.0210 | 171.8490 | 9.7930 | ||||||
Net Income | -738.5550 | -556.3340 | -112.0520 | 263.4840 | 2,096.8960 |
Per Share
Cash Flow
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | -513.1990 | -365.4320 | 236.1030 | 844.9420 | 1,270.2860 | ||||||
Cash Flow from Investing Activities | 73.9590 | 268.8560 | 104.4690 | -437.6810 | -202.1580 | ||||||
Cash Flow from Financing | 497.3760 | 188.9190 | 133.2710 | 68.4040 | -71.2190 | ||||||
Decrease / Increase in Cash | 55.9600 | 89.5090 | 469.1770 | 481.4670 | 990.7270 | ||||||
Employees | 1,830 | 1,950 | 2,150 | 2,300 | 2,500 |